- Home
- BMRN vs AKAM Comparison
BMRN vs AKAM Comparison
Compare BMRN & AKAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- AKAM
- Stock Information
- Founded
- BMRN 1996
- AKAM 1998
- Country
- BMRN United States
- AKAM United States
- Employees
- BMRN N/A
- AKAM N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- AKAM Business Services
- Sector
- BMRN Health Care
- AKAM Consumer Discretionary
- Exchange
- BMRN Nasdaq
- AKAM Nasdaq
- Market Cap
- BMRN 11.1B
- AKAM 11.4B
- IPO Year
- BMRN 1999
- AKAM 1999
- Fundamental
- Price
- BMRN $54.09
- AKAM $76.84
- Analyst Decision
- BMRN Buy
- AKAM Hold
- Analyst Count
- BMRN 24
- AKAM 16
- Target Price
- BMRN $91.70
- AKAM $92.60
- AVG Volume (30 Days)
- BMRN 1.8M
- AKAM 1.7M
- Earning Date
- BMRN 10-28-2025
- AKAM 11-06-2025
- Dividend Yield
- BMRN N/A
- AKAM N/A
- EPS Growth
- BMRN 154.69
- AKAM N/A
- EPS
- BMRN 3.40
- AKAM 2.82
- Revenue
- BMRN $3,063,608,000.00
- AKAM $4,083,251,000.00
- Revenue This Year
- BMRN $13.32
- AKAM $6.69
- Revenue Next Year
- BMRN $9.37
- AKAM $5.12
- P/E Ratio
- BMRN $15.91
- AKAM $27.24
- Revenue Growth
- BMRN 18.36
- AKAM 3.98
- 52 Week Low
- BMRN $52.93
- AKAM $67.51
- 52 Week High
- BMRN $85.00
- AKAM $106.80
- Technical
- Relative Strength Index (RSI)
- BMRN 37.63
- AKAM 48.73
- Support Level
- BMRN $55.99
- AKAM $76.51
- Resistance Level
- BMRN $59.79
- AKAM $79.41
- Average True Range (ATR)
- BMRN 1.57
- AKAM 1.65
- MACD
- BMRN -0.40
- AKAM 0.06
- Stochastic Oscillator
- BMRN 0.70
- AKAM 22.22
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.